Concepedia

M. D’Arcangelo

MD

Statistics

Publications

19

Citations

1.4K

H-Index

14

Active since

2009

Affiliations

Azienda Unità Sanitaria Locale Della Romagna(Current)

Istituti di Ricovero e Cura a Carattere Scientifico

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Fondazione IRCCS Istituto Nazionale dei Tumori

University of Colorado Cancer Center

M. D’Arcangelo is an author at Azienda Unità Sanitaria Locale Della Romagna specializing in oncology, medicine, and molecular oncology.

ORCID

Publications per year

2009–2025

19

Publications

19

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

José Trigo, Vivek Subbiah, Benjamin Besse et al. · The Lancet Oncology · 2020 · 462 citations

, , +9

Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC

Byoung Chul Cho, Shun Lu, Enriqueta Felip et al. · New England Journal of Medicine · 2024 · 375 citations · Full text

, , +14

Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer

Andrea Fontana, Luca Galli, Anna Fioravanti et al. · Clinical Cancer Research · 2009 · 88 citations

, , +17

Overall Survival with Amivantamab–Lazertinib in <i>EGFR</i> -Mutated Advanced NSCLC

James Chih‐Hsin Yang, Shun Lu, Hidetoshi Hayashi et al. · New England Journal of Medicine · 2025 · 85 citations

, , +15

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial

Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino et al. · Journal of Thoracic Oncology · 2022 · 68 citations · Full text

, , +9

1–5 of 19